Abstract 183P
Background
Personalized targeted cancer treatment strongly depends on genetic tests in tumor tissue. Meanwhile, it is essential to understand the oncogenicity of a large number of somatic and germline variants to identify potential drug targets, which can be used for further treatment. An adopted classification scheme to guide variant oncogenicity assessment has to be easy, fast and reproducible. In this study we implemented a full-fledged database SomaVar and web-based frontend for somatic variant upload, annotation and classification using the VICC classification guidelines.
Methods
The frontend provides a multitude of utility functions which include an advanced variant search, user defined variant lists, automatic classification criteria selection and extensive administrative utilities. SomaVar supports variant annotation including in-silico pathogenicity prediction scores, splicing prediction scores, third party classifications, population scores and protein domains. SomaVar has a semi-automatic classification algorithm for oncogenicity based on the VICC standards and allows harmonized consensus classification between different users.
Results
Using a list of variants already classified by experts we show that the automatic classification algorithm provides a high-quality preselection for most VICC criteria. This not only increases the speed at which experts can classify variants, but also increases quality by mitigating human error. We also compared our knowledgebase to OnkoKB. A large overlap was found within the both groups of variants of likely oncogenic and of unclear oncogenicity variants. Interestingly, divergent classification was observed for variants located within splice regions and for benign variants listed in gnomAD at high allele frequencies.
Conclusions
To date, our knowledgebase harbors over 20.000 classified somatic variants and continues to grow. This open-source knowledgebase is publicly available online.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
151P - Unravelling the limitations of next-generation sequencing (NGS)-based liquid biopsy (LB) across solid tumors: The PREICO-LB project
Presenter: Cinta Hierro
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping
Presenter: Khashayar Roohollahi
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - Discovery of new BRCA1/2 mutations not described in the international breast consortium
Presenter: Wala Ben Kridis
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - Alternative splicing in non-small cell lung cancer evolution
Presenter: Michelle Leung
Session: Cocktail & Poster Display session
Resources:
Abstract
155TiP - Exploring mechanisms of action and resistance to innovative therapeutic drugs: UNLOCK program
Presenter: Julieta Rodriguez
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - Therapeutic potential of B7-H3 targeting in pediatric neuroblastoma
Presenter: Caroline E Nunes-Xavier
Session: Cocktail & Poster Display session
Resources:
Abstract
158P - E-JIB-04: An epigenetic targeted therapy for ovarian cancer with MECOM amplification
Presenter: Ibha Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - The impact of kisspeptin pre-treatment towards temozolomide resistance mechanisms and associated differently expressed proteins (DEPs) in human glioblastoma cells
Presenter: Isra Sati
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - Clinical observation and immune effects of high-intensity focused ultrasound (HIFU) in the treatment of liver metastasis in colorectal cancer
Presenter: Shasha Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - Early phase cancer clinical trials: A viable treatment option for patients?
Presenter: Rhona Dawson
Session: Cocktail & Poster Display session
Resources:
Abstract